Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir in Heart Transplantation
NCT04904614Phase 4Completed
- Sponsor
- Tufts Medical Center
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of letermovir in cytomegalovirus infection (CMV), sponsored by Tufts Medical Center. Primary endpoint: Proportion of Patients With Neutropenia Compared to Historical Controls at 12 months. Started Jan 2022; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT04904614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04904614.